Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...

SAVING’ jab for severe asthma that could prevent deadly attacks with just two doses a year could be available to patients in ...

Two replicate phase 3 trials of GB-0895, an anti-thymic stromal lymphopoietin antibody, are enrolling adults and adolescents ...

More must be done to ensure that asthma patients get access to cutting-edge treatments, experts have said, after research ...

Six key groups must exercise caution before taking atenolol, according to NHS guidance - here's everything you should know.

What is Exdensur? A new FDA-approved asthma biologic from GSK that only needs two doses a year for severe eosinophilic asthma ...

An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two doses annually. Phase 3 trials demonstrated significant reductions in asthma ...

Children conceived through assisted reproductive technology (ART) were modestly more likely to develop asthma, allergic ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced.

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...

An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...